查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584742

抗憂鬱症市場：按藥物類別、適應症、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Antidepressants Drugs Market by Drug Class, Indication, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗憂鬱症市值為207.1億美元，預計到2024年將達到224.4億美元，複合年成長率為9.85%，到2030年將達到399.9億美元。

抗憂鬱症包括多種藥物，包括 SSRIs、SNRIs、MAOIs 和三環抗憂鬱藥物，主要用於治療憂鬱症和相關疾病，如焦慮症、強迫性精神官能症和創傷後壓力症候群 (PTSD)。這些藥物透過改變大腦中的化學失衡來發揮作用，而大腦中的化學失衡被認為與情緒變化和情緒狀態有關。由於精神健康障礙盛行率上升、意識提高以及圍繞精神健康治療的恥辱感減少，抗憂鬱症的需求正在增加。這些藥物已廣泛應用於各種最終用戶，包括醫院、診所和家庭環境。關鍵的成長要素包括全球患者人數的不斷擴大以及藥物配方和藥物傳遞系統的進步，以提高療效並減少副作用。此外，遠端醫療和線上心理健康服務等趨勢正在擴大抗憂鬱症的供應和可近性。然而，這個市場在某些文化中仍然面臨局限性，包括心理健康藥物仍然存在的恥辱、潛在的副作用以及心理治療和生活方式干涉等替代療法的可用性。從潛在商機來看，個人化醫療以及開發副作用更少、起效更快的藥物有很大的技術創新空間。此外，在生物標記發現方面存在更好的診斷和治療工具以及在藥物發現過程中使用人工智慧的機會。然而，他們面臨嚴格的監管要求、專利到期以及先進藥物高成本等挑戰。神經可塑性和遺傳標記等研究領域可能會出現創新治療方法，而公司可能會專注於透過策略聯盟和合作研究來擴大區域市場。該市場競爭激烈，有多家大型製藥公司和快速成長的學名藥製造商。

主要市場統計
基準年[2023] 207.1億美元
預測年份 [2024] 224.4億美元
預測年份 [2030] 399.9億美元
複合年成長率（%） 9.85%

市場動態：揭示快速發展的抗憂鬱症市場的關鍵市場洞察

供需的動態交互作用正在改變抗憂鬱症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 創傷後壓力症候群（PTSD）、強迫性精神官能症和焦慮症的增加
    • 積極的政府措施和宣傳活動來解決心理健康問題
    • 精神衛生機構和專業人員數量的增加
  • 市場限制因素
    • 與抗憂鬱症相關的副作用和費用
  • 市場機會
    • 開發新型抗憂鬱症的創新解決方案
    • 增加新藥的監管核准和增加 SSRIs 的使用
  • 市場挑戰
    • 圍繞心理健康治療的社會恥辱

波特的五力：駕馭抗憂鬱症市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗憂鬱症市場的外部影響

外部宏觀環境因素在塑造抗憂鬱症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗憂鬱症市場的競爭狀況

抗憂鬱症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV抗憂鬱症市場定位矩陣供應商績效評估

FPNV定位矩陣是評估抗憂鬱症市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製抗憂鬱症市場的成功之路

抗憂鬱症市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 創傷後壓力症候群 (PTSD)、強迫症 (OCD) 和焦慮症的發生率增加
      • 關於心理健康問題的有利政府措施和宣傳活動
      • 心理健康機構和專業人員的增加
    • 抑制因素
      • 與抗憂鬱症相關的副作用和費用
    • 機會
      • 新開發抗憂鬱症的創新解決方案
      • 新藥的監管核准增加和 SSRI 藥物的使用增加
    • 任務
      • 圍繞心理健康治療的社會恥辱
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的抗憂鬱症市場

  • 單胺氧化酵素抑制劑
  • 再回收抑制劑
  • 選擇性血清素再回收抑制劑
  • 血清素拮抗劑
  • 正腎上腺素再回收抑制劑
  • 三環抗憂鬱藥物

抗憂鬱症依適應症分類的抗憂鬱藥市場

  • 焦慮症
  • 注意力不足過動症
  • 重度憂鬱症

抗憂鬱症市場：依給藥途徑

  • 可注射的
  • 口服

第9章抗憂鬱症市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲抗憂鬱症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗憂鬱症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的抗憂鬱症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Alembic Pharma核准美國FDA 批准銷售非專利抗憂鬱症
    • 完成 CinCor Pharma 的收購
    • Zydus核准美國食品藥物管理局批准用於治療憂鬱症的學名藥
    • RA Capital 支持尋求更好抗憂鬱症的新Start-Ups
    • Autobahn籌集資金開發憂鬱症治療藥物ABX-002
    • Axsome Therapeutics 宣布 FDA核准AUVELITY，這是第一個也是唯一一個用於治療成人重度憂鬱症的口服 NMDA 受體拮抗劑
    • Genetika+ ​​贏得了著名的歐洲資助，並將憂鬱症藥物匹配平台推向市場
    • Osmind 獲得 4000 萬美元投資，支持心理健康研究和治療
    • Sun Pharma 計劃在靈北 (Lundbeck) 的獨家專利許可下在印度推出Vortioxetine)版本
    • 艾伯維 (AbbVie) 收購 Syndesi Therapeutics 以加強神經科學產品組合
    • 印度顆粒公司獲得美國FDA核准非專利抗憂鬱症
  • 戰略分析和建議

公司名單

  • AN Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Angelini Pharma Spa
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • CAPLYTA by Intra-Cellular Therapies, Inc.
  • Divi's Laboratories Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Eridanus Healthcare
  • H. Lundbeck A/S
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Neurocon Inc.
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi SA
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Wellona Pharma
Product Code: MRR-742BD517AEC4

The Antidepressants Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Antidepressant drugs, which encompass a broad range of medications such as SSRIs, SNRIs, MAOIs, and tricyclic antidepressants, are primarily designed to manage depression and associated disorders like anxiety, OCD, and PTSD. These medications function by altering chemical imbalances in the brain, which are thought to be responsible for mood changes and emotional states. The necessity for antidepressant drugs has been increasing, driven by the rising prevalence of mental health disorders, increased awareness, and reduced stigma surrounding mental health treatment. These drugs find application across various end-users, including hospitals, clinics, and household settings, making them widely accessible. Key growth factors include an expanding demographic of patients across the globe and advancements in drug formulations and delivery systems that improve efficacy and reduce side effects. Additionally, trends like telemedicine and online mental health services are expanding the reach and accessibility of antidepressants. However, the market faces limitations such as the stigma still attached to mental health medication in some cultures, potential side effects, and the existence of alternative therapies like psychotherapy and lifestyle interventions. Among potential opportunities, there is significant room for innovation in personalized medicine and the development of drugs with fewer side effects and quicker onset of action. Furthermore, opportunities exist in exploring biomarkers for better diagnostic and treatment tools and leveraging artificial intelligence for drug discovery processes. Nonetheless, the market faces challenges like stringent regulatory requirements, patent expirations, and the high cost of advanced medications. Research areas such as neuroplasticity and genetic markers may yield innovative treatments, while companies might focus on regional market expansion through strategic partnerships and collaborations. The nature of the market is highly competitive, characterized by the presence of several large pharmaceutical companies and growing generic drug manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 20.71 billion
Estimated Year [2024] USD 22.44 billion
Forecast Year [2030] USD 39.99 billion
CAGR (%) 9.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antidepressants Drugs Market

The Antidepressants Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of PTSD, OCD, and anxiety issues
    • Favorable government initiatives and campaigns for mental health problems
    • Rise in number of mental health institutions and professionals
  • Market Restraints
    • Associated side effects and cost of antidepressants drugs
  • Market Opportunities
    • Innovative solutions for the development of novel antidepressants drugs
    • Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
  • Market Challenges
    • Social stigma surrounding mental health treatments

Porter's Five Forces: A Strategic Tool for Navigating the Antidepressants Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antidepressants Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antidepressants Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antidepressants Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antidepressants Drugs Market

A detailed market share analysis in the Antidepressants Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antidepressants Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antidepressants Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antidepressants Drugs Market

A strategic analysis of the Antidepressants Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidepressants Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Angelini Pharma S.p.a., Apotex Inc., AstraZeneca PLC, Biogen Inc., Bristol Myers Squibb Company, CAPLYTA by Intra-Cellular Therapies, Inc., Divi's Laboratories Limited, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Eridanus Healthcare, H. Lundbeck A/S, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Mallinckrodt PLC, Merck & Co., Inc., Midas Pharma GmbH, Neurocon Inc., Organon & Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Somacare, SteriMax Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Antidepressants Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Monoamine Oxidase Inhibitors, Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Serotonin Antagonist, Serotonin-Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants.
  • Based on Indication, market is studied across Anxiety Disorders, Attention Deficit Hyperactivity Disorder, and Major Depressive Disorder.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of PTSD, OCD, and anxiety issues
      • 5.1.1.2. Favorable government initiatives and campaigns for mental health problems
      • 5.1.1.3. Rise in number of mental health institutions and professionals
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects and cost of antidepressants drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative solutions for the development of novel antidepressants drugs
      • 5.1.3.2. Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Social stigma surrounding mental health treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antidepressants Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Monoamine Oxidase Inhibitors
  • 6.3. Reuptake Inhibitors
  • 6.4. Selective Serotonin Reuptake Inhibitors
  • 6.5. Serotonin Antagonist
  • 6.6. Serotonin-Norepinephrine Reuptake Inhibitors
  • 6.7. Tricyclic Antidepressants

7. Antidepressants Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety Disorders
  • 7.3. Attention Deficit Hyperactivity Disorder
  • 7.4. Major Depressive Disorder

8. Antidepressants Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Antidepressants Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Antidepressants Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antidepressants Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antidepressants Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Alembic Pharma gets USFDA nod to market generic antidepressant drug
    • 13.3.2. Acquisition of CinCor Pharma complete
    • 13.3.3. Zydus gets USFDA nod to market generic medicine for treating depression
    • 13.3.4. RA Capital backs another startup hunting for a better antidepressant
    • 13.3.5. Autobahn raises funds for ABX-002 advancement to treat depression
    • 13.3.6. Axsome Therapeutics Announces FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
    • 13.3.7. Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
    • 13.3.8. Osmind scores $40M investment to aid in mental health research and treatment
    • 13.3.9. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
    • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
    • 13.3.11. Granules India gets USFDA approval for generic antidepressant drug
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. N. Pharmacia Laboratories Pvt. Ltd.
  • 2. AbbVie Inc.
  • 3. Alkermes PLC
  • 4. Angelini Pharma S.p.a.
  • 5. Apotex Inc.
  • 6. AstraZeneca PLC
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. CAPLYTA by Intra-Cellular Therapies, Inc.
  • 10. Divi's Laboratories Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eisai Co., Ltd.
  • 13. Eli Lilly and Company
  • 14. Eridanus Healthcare
  • 15. H. Lundbeck A/S
  • 16. Jabs Biotech Pvt. Ltd.
  • 17. Johnson & Johnson Services, Inc.
  • 18. La Renon Healthcare Pvt. Ltd.
  • 19. Lupin Ltd.
  • 20. Mallinckrodt PLC
  • 21. Merck & Co., Inc.
  • 22. Midas Pharma GmbH
  • 23. Neurocon Inc.
  • 24. Organon & Co.
  • 25. Otsuka Pharmaceutical Co., Ltd.
  • 26. Pfizer Inc.
  • 27. Sandoz International GmbH by Novartis AG
  • 28. Sanofi S.A.
  • 29. Somacare
  • 30. SteriMax Inc.
  • 31. Sun Pharmaceutical Industries Limited
  • 32. Takeda Pharmaceutical Co. Ltd.
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. UCB S.A.
  • 35. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. ANTIDEPRESSANTS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIDEPRESSANTS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIDEPRESSANTS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023